Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 20th, 2013% Cheryl Gregory-Evans (University of British Columbia)
Medical researchers at University of British Columbia in Vancouver, Canada adapted a new drug as a treatment for aniridia, a rare eye disease caused by a birth defect, with tests on mice showing the drug’s potential effectiveness in treating the disorder. The team from UBC and the . . . → Read More: Drug Fixes Vision Birth Defect in Lab Tests, Trial Planned
By Alan, on December 20th, 2013% Sugar beet (Agricultural Research Service/USDA)
Geneticists and computer scientists in Germany, Spain, and Sweden sequenced the genome of the sugar beet, a plant contributing a large segment of the world’s sugar production. The study offers an analytical reference for advances in biotechnology with implications for agriculture and renewable energy.
The team led by . . . → Read More: Sugar Beet Genome Sequenced, Human Impact on Species Noted
By Alan, on December 19th, 2013% (Photos8.com)
Researchers at Virginia Commonwealth University in Richmond found regular monthly appointments with pharmacists can help patients keep taking their medications as prescribed. Pharmacy professor David Holdford and then-doctoral candidate Timothy Inocencio published their findings in the current issue of the Journal of the American Pharmacists Association (subscription required).
A study published earlier . . . → Read More: Monthly Pharmacist Appointments Improve Medication Adherence
By Alan, on December 19th, 2013% (M4D Group/Flickr)
The global pharmaceutical company Bayer Group based in Germany is buying the specialty drug company Algeta ASA in Oslo, Norway for NOK 17.6 billion (USD 2.9 billion). Algeta, developer of a radium-based drug to treat prostate cancer, says its board of directors approved the sale, subject to confirmation by shareholders.
Bayer . . . → Read More: Bayer Acquires Cancer Drug Developer Algeta for $2.9B
By Alan, on December 18th, 2013% (NLM.NIH.gov)
An early stage clinical trial by California Stem Cell Inc. in Irvine tested a therapy harnessing the body’s immune system to treat a common form of liver cancer. The trial, conducted with eight patients in Shanghai, China, showed the treatments were safe for patients with hepatocellular carcinoma and did not cause complications, according . . . → Read More: Early Trial Tests Stem Cell Immunotherapy for Liver Cancer
By Alan, on December 17th, 2013% (A. Kotok)
National Institutes of Health (NIH) is supporting three new projects with technical research services for two companies and one university lab developing therapies for rare diseases. The projects aim to develop treatments for acute radiation syndrome, brain injury following cardiac arrest, and beta thalassemia, a rare blood disorder.
The awards are . . . → Read More: NIH Giving In-Kind Technical Services for Rare Diseases
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.